Neurologic Imaging

What Is the Best Initial Imaging for Chorea in Suspected Huntington Disease?

·
What Is the Best Initial Imaging for Chorea in Suspected Huntington Disease?

A 42-year-old patient presents to your clinic with a six-month history of subtle, involuntary, dance-like movements in his arms and face. He also reports increased irritability and difficulty concentrating at work. His father, he recalls, developed a similar “shaking condition” in his 50s but was never formally diagnosed. You suspect Huntington disease, but the diagnosis requires a careful workup. Your immediate question is what imaging, if any, to order first to evaluate the structural changes associated with this condition and rule out mimics. This article details the clinical workflow for this exact scenario, guided by the American College of Radiology (ACR) Appropriateness Criteria, which rate an MRI head without IV contrast as Usually Appropriate.

Who Fits This Clinical Scenario for Suspected Huntington Disease?

This guidance applies to patients, typically between the ages of 30 and 50, presenting with a new subacute or chronic hyperkinetic movement disorder, specifically chorea. The clinical picture is often accompanied by a triad of motor, cognitive, and psychiatric symptoms. A positive family history of an autosomal dominant neurodegenerative disorder is a strong, though not essential, indicator. The primary goal of imaging in this initial workup is to identify characteristic patterns of brain atrophy and to exclude other structural causes.

This workflow is specifically for the initial evaluation of suspected Huntington disease (HD) and is not intended for:

  • Patients with rapidly progressive dementia and myoclonus. This presentation raises suspicion for Creutzfeldt-Jakob disease, which has a distinct imaging pathway focused on identifying characteristic diffusion restriction patterns on MRI.
  • Patients with primary parkinsonian syndromes. Individuals whose primary symptoms are bradykinesia, rigidity, and resting tremor should be evaluated under the parkinsonism imaging criteria, which may involve different MRI sequences or functional imaging like DaTscan in certain contexts.
  • Patients with suspected neurodegeneration with brain iron accumulation (NBIA). Presentations involving a combination of parkinsonism, dystonia, and spasticity, especially in younger patients, may warrant specific MRI sequences (like susceptibility-weighted imaging) to detect iron deposition, a different diagnostic question.

Correctly identifying the patient’s dominant clinical syndrome is crucial for selecting the most appropriate imaging pathway.

What Diagnoses Are You Working Up with Imaging for Chorea?

While Huntington disease is the primary suspicion, the differential for chorea is broad. Initial imaging serves to either support the suspected diagnosis or point toward an alternative etiology.

Huntington Disease (HD) is the leading consideration. This autosomal dominant trinucleotide repeat disorder causes progressive, selective neurodegeneration. Imaging is used to detect the hallmark finding: atrophy of the caudate nucleus and, to a lesser extent, the putamen. The degree of this striatal atrophy often correlates with disease severity and can be quantified using various radiological scoring systems.

Huntington Disease-Like (HDL) Syndromes are a group of genetic disorders that clinically mimic HD but are caused by different mutations. These conditions can also cause chorea and cognitive decline. While imaging findings can overlap with HD, such as demonstrating striatal atrophy, subtle differences may exist, and a “classic HD” imaging pattern in the setting of a negative genetic test for HD may prompt further genetic investigation for these mimics.

Wilson Disease is a critical, treatable diagnosis to consider, especially in younger patients. This autosomal recessive disorder of copper metabolism can present with a wide range of neurologic and psychiatric symptoms, including chorea. MRI can reveal characteristic signal abnormalities in the basal ganglia (particularly the putamen), thalamus, and brainstem, which differ from the purely atrophic changes of HD.

Neuroacanthocytosis represents a rare group of inherited disorders characterized by progressive neurodegeneration, movement disorders (including chorea), and misshapen red blood cells (acanthocytes). The most common forms, such as chorea-acanthocytosis, often demonstrate prominent caudate atrophy on MRI that can be indistinguishable from that seen in Huntington disease.

Finally, imaging helps exclude structural mimics. Although less common in a patient with a progressive, familial presentation, chorea can be caused by focal lesions. A structural MRI can confidently rule out causes like a subthalamic nucleus stroke, a strategically located brain tumor, or an inflammatory or demyelinating lesion affecting the basal ganglia.

Why Is MRI Head without IV Contrast the Recommended Initial Study?

The ACR rates MRI head without IV contrast as Usually Appropriate for the initial imaging of a patient with chorea and suspected Huntington disease. This recommendation is based on the modality’s superior ability to visualize the key anatomical structures without exposing the patient to ionizing radiation or intravenous contrast agents.

The primary role of imaging in this scenario is to assess for selective volume loss in the basal ganglia. Non-contrast MRI provides excellent soft-tissue resolution, allowing for clear visualization and quantification of caudate and putaminal atrophy. In established HD, the heads of the caudate nuclei become flattened or concave, causing the adjacent frontal horns of the lateral ventricles to appear enlarged and squared-off—the classic “boxcar” appearance. MRI can detect these changes with high sensitivity, often before they become apparent on other modalities.

Alternative studies are rated lower for specific reasons:

  • CT head without IV contrast is rated May be appropriate. While a non-contrast CT can demonstrate advanced caudate atrophy and the resulting ventricular enlargement, its sensitivity for detecting early or subtle volume loss is substantially lower than MRI. It remains a viable alternative when MRI is contraindicated (e.g., incompatible implanted device) or unavailable. However, it involves ionizing radiation (adult RRL ☢☢☢ 1-10 mSv).
  • FDG-PET/CT brain is rated Usually not appropriate for initial diagnosis. While PET imaging can reveal characteristic hypometabolism in the caudate and putamen, often preceding visible atrophy, it is not a first-line tool. It is more invasive, involves significant radiation exposure (adult RRL ☢☢☢ 1-10 mSv), and is typically reserved for research settings or diagnostically challenging cases where structural imaging is unrevealing.

The choice of a non-contrast MRI protocol is deliberate. Since the diagnostic goal is to evaluate brain morphology and atrophy, intravenous gadolinium-based contrast adds little to no value. An MRI head without and with IV contrast is rated May be appropriate but is not the preferred first step, as it introduces the small risks associated with contrast agents without improving the detection of HD-related atrophy. The non-contrast study provides all the necessary information with zero ionizing radiation (adult RRL O 0 mSv).

What’s Next After the MRI? Downstream Workflow

The results of the initial MRI guide the subsequent diagnostic and management steps. While imaging can be highly suggestive, the definitive diagnosis of Huntington disease relies on genetic testing.

If the MRI shows characteristic caudate and/or putaminal atrophy: This finding strongly supports a diagnosis of Huntington disease or an HDL syndrome. The essential next step is genetic counseling followed by confirmatory genetic testing for the HTT gene expansion. A positive genetic test confirms the diagnosis. If the HTT test is negative despite suggestive imaging, referral to a movement disorder specialist is crucial to consider testing for rarer HDL syndromes.

If the MRI is normal: A normal MRI, particularly in a patient with early or mild symptoms, does not exclude Huntington disease. Atrophy may not be radiologically apparent in the earliest stages of the disease. If clinical suspicion remains high based on the chorea and family history, proceeding with genetic counseling and testing is still the appropriate next step.

If the MRI shows an unexpected finding:

  • Findings suggestive of Wilson disease (e.g., T2 hyperintensity in the basal ganglia/thalamus): The workup should immediately pivot. Next steps include ophthalmologic evaluation for Kayser-Fleischer rings, serum ceruloplasmin and copper levels, and a 24-hour urinary copper excretion test.
  • Evidence of a stroke, tumor, or inflammatory lesion: The patient’s diagnosis is not a primary neurodegenerative condition. The downstream workflow will be dictated by the specific finding, requiring referral to the appropriate specialist (e.g., stroke neurology, neuro-oncology) for further management.

In all cases, the imaging results must be interpreted in the context of the full clinical picture.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected Huntington disease requires careful consideration to avoid common diagnostic errors.

First, do not rely solely on imaging to rule out Huntington disease. A normal MRI in an early-stage patient is a common finding. The diagnosis is ultimately genetic, and imaging serves as a supportive tool and a method to exclude mimics.

Second, avoid ordering a CT as the primary study unless MRI is clearly contraindicated. The superior soft-tissue contrast and sensitivity of MRI for detecting subtle atrophy make it the far more powerful tool for this specific clinical question.

Third, do not mistake age-related or nonspecific global atrophy for the selective caudate atrophy of HD. The pattern is key. Look for disproportionate volume loss in the caudate heads relative to other brain structures. If the findings are equivocal, a formal radiology report with volumetric comparison or a neuroradiologist’s opinion can be invaluable.

If the clinical picture and imaging findings are discordant (e.g., classic chorea with a normal MRI and negative HTT genetic test), it is time to escalate. Referral to a specialized movement disorders center is the appropriate next step for a comprehensive evaluation for rare genetic mimics and other etiologies.

Related ACR Topics and Tools

This article focuses on a single clinical scenario. For a broader view of imaging for other related conditions, and for tools to help in ordering and interpreting these studies, the following resources are available:

Frequently Asked Questions

Is genetic testing or imaging the first step for suspected Huntington disease?

Genetic testing is the definitive diagnostic test for Huntington disease. However, initial neuroimaging with a non-contrast head MRI is considered ‘Usually Appropriate’ by the ACR. It plays a crucial role in supporting the clinical diagnosis by identifying characteristic atrophy and, importantly, ruling out structural mimics like stroke, tumors, or other metabolic disorders that can present with chorea.

Why is a non-contrast MRI preferred over an MRI with contrast?

The primary diagnostic goal in this scenario is to assess for a specific pattern of brain volume loss (atrophy), particularly in the caudate nucleus. Non-contrast MRI sequences provide excellent anatomical detail for this purpose. Intravenous contrast is used to highlight areas of inflammation or breakdown of the blood-brain barrier, which are not features of Huntington disease. Therefore, adding contrast does not provide additional diagnostic information for this indication and introduces unnecessary risk and cost.

Can a normal MRI rule out Huntington disease?

No. A normal MRI does not exclude Huntington disease, especially in the early stages of the illness. Significant brain atrophy is a feature of more established disease, and imaging may appear normal for years after symptom onset. If clinical suspicion is high based on the movement disorder and family history, genetic counseling and testing should be pursued regardless of the MRI findings.

What is the ‘boxcar’ sign on imaging for Huntington disease?

The ‘boxcar’ sign refers to the appearance of the frontal horns of the lateral ventricles on axial imaging (CT or MRI). In Huntington disease, the heads of the caudate nuclei, which form the lateral walls of these ventricles, undergo severe atrophy. This volume loss causes the normally rounded walls to become flat or concave, making the ventricles appear squared-off or box-shaped. It is a classic, though typically late, sign of the disease.

If my patient cannot get an MRI, is a CT scan a reasonable alternative?

Yes, a CT head without IV contrast is rated as ‘May be appropriate’ by the ACR and is a reasonable alternative if MRI is contraindicated (e.g., due to an incompatible pacemaker or severe claustrophobia). While less sensitive than MRI for detecting early atrophy, a CT can still identify the more advanced changes of Huntington disease, such as ‘boxcar’ ventricles, and is effective at ruling out major structural mimics like a large tumor or hemorrhage.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026